dc.contributor.author | von Itzstein, Mitchell S | |
dc.contributor.author | Khan, Shaheen | |
dc.contributor.author | Popat, Vinita | |
dc.contributor.author | Lu, Rong | |
dc.contributor.author | Khan, Saad A | |
dc.contributor.author | Fattah, Farjana J | |
dc.contributor.author | Park, Jason Y | |
dc.contributor.author | Bermas, Bonnie L | |
dc.contributor.author | Karp, David R | |
dc.contributor.author | Ahmed, Murtaza | |
dc.contributor.author | Saltarski, Jessica M | |
dc.contributor.author | Gloria-McCutchen, Yvonne | |
dc.contributor.author | Xie, Yang | |
dc.contributor.author | Li, Quan-Zhen | |
dc.contributor.author | Wakeland, Edward K | |
dc.contributor.author | Gerber, David E | |
dc.date.accessioned | 2020-06-02T23:58:17Z | |
dc.date.available | 2020-06-02T23:58:17Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1083-7159 | |
dc.identifier.doi | 10.1634/theoncologist.2019-0911 | |
dc.identifier.uri | http://hdl.handle.net/10072/394330 | |
dc.description.abstract | Immune-related adverse events induced by immune checkpoint inhibitor (ICI) therapy may affect diverse organ systems, including skeletal and cardiac muscle. ICI-associated myositis may result in substantial morbidity and occasional mortality. We present a case of a patient with advanced non-small cell lung cancer who developed grade 4 myositis with concurrent myocarditis early after initiation of anti-programmed death ligand 1 therapy (durvalumab). Autoantibody analysis revealed marked increases in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody levels that preceded clinical toxicity, and further increased during toxicity. Notably, the patient had a history of intolerable statin myopathy, which had resolved clinically after statin discontinuation and prior to ICI initiation. This case demonstrates a potential association between statin exposure, autoantibodies, and ICI-associated myositis. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Alphamed Press | |
dc.relation.ispartofjournal | Oncologist | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearchcode | 3211 | |
dc.title | Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition? | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | von Itzstein, MS; Khan, S; Popat, V; Lu, R; Khan, SA; Fattah, FJ; Park, JY; Bermas, BL; Karp, DR; Ahmed, M; Saltarski, JM; Gloria-McCutchen, Y; Xie, Y; Li, Q-Z; Wakeland, EK; Gerber, DE, Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?, Oncologist, 2020 | |
dcterms.dateAccepted | 2020-04-16 | |
dc.date.updated | 2020-06-02T05:45:07Z | |
gro.description.notepublic | This publication has been entered in Griffith Research Online as an advanced online version. | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Von Itzstein, Mitchell S. | |